Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

umulative toxicity or long-term safety concerns with a median follow-up of 16 months for treated patients.

Study Methodology and Results

116 CLL patients were enrolled in the study in a series of treatment cohorts, which included patients who were never treated (treatment-nave); those who had received two or more prior therapies (relapsed/refractory); those who had relapsed within two years of treatment (high-risk); and those over age 65. Two oral dosing regimens (420 mg or 840 mg) of ibrutinib were used daily. The primary goal of the study was to determine the safety of the low and high doses. Secondary objectives included efficacy, measures of the intensity of the drug's effect in the body and the long-term safety of administering continuously until relapse.

The majority of adverse effects were diarrhea (54%), fatigue (29%), upper respiratory tract infection (29%), rash (28%), nausea (26%) and arthralgias (25%). Hematologic toxicity ≥ Gr 3 was relatively infrequent. There was no evidence of cumulative toxicity or long-term safety concerns with a median follow-up of 16 months. Estimated 22 month progression free survival for the 85 relapsed or refractory and high-risk patients was 76 percent and 96 percent for treatment-nave patients. Estimated 22 month overall survival for the 85 relapsed or refractory patients and high-risk patients was 85 percent and 96 percent for treatment-nave patients. Funding from Pharmacyclics, Inc., supports this clinical trial.


'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... announcement (PSA) campaign that empowers parents to talk to ... dangers of underage drinking, was launched today by the ... , The kickoff occurred in conjunction with SAMHSA’s 2013 ... awareness of, and action around, substance abuse and mental ...
(Date:5/23/2013)... Susquehanna Health is now ... babysitting training course for adolescents age 11 and up. ... pediatrician Dr. Patricia Keener after a colleague’s toddler choked ... sitter who didn’t know how to provide first aid. ... a medical basis that aims to reduce the number ...
(Date:5/23/2013)... Live Lead Pros , with its ... business lead solution via its smart solution for ... features Free Web Based Account Management, Database Usage, ... "Automatic Transfer Retry". The company has recently announced ... system. , Its Free Database Usage offers their ...
(Date:5/23/2013)... dragged to its destruction inside a cell, a ... that thwart the development of tumor-suppressing microRNAs (miRNAs) ... online publication at Nature . , Under ... the epidermal growth factor receptor (EGFR) gums up ... by scientists at The University of Texas MD ...
(Date:5/23/2013)... about to be tested in a clinical trial by ... for Alzheimer,s disease has failed to work with the ... according to results of a study by University of ... neuroscience affiliated with the Evelyn F. and William L. ... the importance of verifying promising research results before investing ...
Breaking Medicine News(10 mins):Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3
... ADMISSION TO ICU MAY INCREASE RISK OF DEATH , ... have an increased risk of death compared with those ... Philadelphia, Philadelphia, PA, and Eastern Virginia Medical School, Norfolk, ... between time of admission to the ICU and mortality, ...
... appear to be associated with increased rates of mood, anxiety ... report in the June issue of Archives of General ... of child maltreatment and later mental health outcomes have relied ... the article. Doubts have been raised about the reliability and ...
... , MONDAY, July 5 (HealthDay News) -- Too much time ... risk of attention problems in children and young adults, new ... to point out the ill effects of excessive screen time, ... Swing, a graduate student at Iowa State University, compared participants ...
... 7 year study ... and weight loss programs. , , ... (PRWEB) July 6, 2010 -- After conducting a 7 year study with over 1,853 ... to other diet programs - the average weight loss was 22.3 pounds compared to 9 ...
... ... , ... 2010 -- Trek Bicycle, the world leader in bicycle technology and innovation, officially launched its ... of the 2010 Tour de France’s Grand Départ, the incendiary new Madone 6 Series SSL ...
... ... under the Oracle Partner Network program. , ... (PRWEB) July 5, 2010 -- TowerStrides Inc ., a professional provider of ... the Oracle PartnerNetwork (OPN). As an Oracle Gold Partner , TowerStrides intends to continue ...
Cached Medicine News:Health News:News briefs from the July issue of Chest 2Health News:Abused children appear likely to have mental disorders as young adults 2Health News:Too Much Screen Time Can Threaten Attention Span 2Health News:Too Much Screen Time Can Threaten Attention Span 3Health News:Trek Introduces All New 2011 Madone Family of Road Bikes 2Health News:Trek Introduces All New 2011 Madone Family of Road Bikes 3Health News:Trek Introduces All New 2011 Madone Family of Road Bikes 4Health News:TowerStrides Inc. Becomes Oracle PartnerNetwork Gold Level Partner 2Health News:TowerStrides Inc. Becomes Oracle PartnerNetwork Gold Level Partner 3
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
(Date:5/23/2013)... 2013 Amgen (NASDAQ: AMGN ) will ... Conference on Thursday, May 30, 2013, at the Westin Boston ... a.m. Eastern Daylight Time. Arvind Sood , ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:5/23/2013)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... will present at The Deutsche Bank 38 th Annual ... on May 29, 2013 at 1:30pm Eastern time.  ... public may access Mr. Lindop,s presentation live via webcast at: ... Haemonetics (NYSE: HAE ) is a global healthcare ...
Breaking Medicine Technology:
... Phase II Testing Certification with Edifecs CORE Testing Service ... in X12 Version 5010BELLEVUE, Wash., April 5 ... its partners CAQH and Harvard Pilgrim Health Care, examine ... II Certification testing including elements of the newly mandated ...
... SILVER SPRING, Md., April 2 Novo Nordisk today announced ... United States Food and Drug Administration (FDA) has finalized its ... analogue. The Advisory Committee voted on questions related to the ... , A majority ...
Cached Medicine Technology:Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 2Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 3Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 4Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase 5Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 2Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes 3
... The Hub Cap Limited ... to provide outstanding fixation and ... targeted solution for four corner ... the plate offers the kind ...
... cornerstones of the Acutrak family are the ... Together they are used primarily for secure ... upper extremity, but have been used for ... stabilized with these two systems have ranged ...
... decade KMI® revolutionized the wrist arthroplasty market ... Wrist System. We're at it again, with ... the Universal2. Like the original, the Universal2 ... live with debilitating arthritis. To date, we ...
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Medicine Products: